Cytomegalovirus-Specific Hyperimmune Immunoglobulin Administration for Secondary Prevention after First-Trimester Maternal Primary Infection: A 13-Year Single-Center Cohort Study
Viruses · 2024
DOI: 10.3390/v16081241 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Viruses, 2024. Verfasst von Emmanouil Karofylakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fourth Department of Internal Medicine, University General Hospital Attikon, National and Kapodistrian University of Athens, 12462 Athens, Greece. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Infectious Disease Transmission, Vertical, Pregnancy Trimester, First, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary cytomegalovirus infection during pregnancy has a high risk of vertical transmission, with severe fetal sequelae mainly associated with first-trimester infections. We conducted a retrospective analysis of 200 IU/kg cytomegalovirus-specific hyperimmune globulin (HIG), used in first-trimester maternal primary infections for congenital infection prevention. The primary outcome was vertical transmission, defined as neonatal viruria or positive amniocentesis if pregnancy was discontinued. HIG, initially administered monthly and since 2019 biweekly, was discontinued in negative amniocentesis cases. Women declining amniocentesis and positive amniocentesis cases with normal sonography were offered monthly HIG until delivery as a treatment strategy. The total transmission rate was 29.9% (32/107; 10 pregnancy terminations with positive amniocentesis, 18 completed pregnancies with positive amniocentesis and 4 declining amniocentesis). Maternal viremia was the only factor associated with fetal transmission (OR 4.62, 95% CI 1.55–13.74). The transmission rate was not significantly different whether HIG was started during the first or second trimester (28.2% vs. 33.3%; p = 0.58), or between monthly and biweekly subgroups (25.7% vs. 37.8%, p = 0.193). Pre-treatment maternal viremia could inform decisions as a predictor of congenital infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fourth Department of Internal Medicine, University General Hospital Attikon, National and Kapodistrian University of Athens, 12462 Athens, Greece.
- Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
- 1st Department of Internal Medicine-Infectious Diseases, Hygeia General Hospital, 4 Erythrou Stavrou & Kifisias, Marousi, 15123 Athens, Greece.
- Third Department of Pediatrics, University General Hospital Attikon, National and Kapodistrian University of Athens, 12462 Athens, Greece.
ORCID-Profile: Emmanouil Karofylakis, Konstantinos Thomas, Lamprini Galani, Sotirios Tsiodras, Anastasia Antoniadou
Zitieren
APA
Karofylakis, E., Thomas, K., Kavatha, D., Galani, L., Tsiodras, S., Giamarellou, H., Papaevangelou, V., & Antoniadou, A. (2024). Cytomegalovirus-Specific Hyperimmune Immunoglobulin Administration for Secondary Prevention after First-Trimester Maternal Primary Infection: A 13-Year Single-Center Cohort Study. Viruses. https://doi.org/10.3390/v16081241
Vancouver
Karofylakis E, Thomas K, Kavatha D, Galani L, Tsiodras S, Giamarellou H, et al. Cytomegalovirus-Specific Hyperimmune Immunoglobulin Administration for Secondary Prevention after First-Trimester Maternal Primary Infection: A 13-Year Single-Center Cohort Study. Viruses. 2024. doi:10.3390/v16081241
BibTeX
@article{Karofylakis2024,
author = {Karofylakis, Emmanouil and Thomas, Konstantinos and Kavatha, Dimitra and Galani, Lamprini and Tsiodras, Sotirios and Giamarellou, Helen and Papaevangelou, Vassiliki and Antoniadou, Anastasia},
title = {Cytomegalovirus-Specific Hyperimmune Immunoglobulin Administration for Secondary Prevention after First-Trimester Maternal Primary Infection: A 13-Year Single-Center Cohort Study},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16081241}
}
EUVIMED